Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Schedule A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LX4211 | EXPERIMENTAL | 400 mg of LX4211 administered orally |
| Placebo | PLACEBO_COMPARATOR | Nonidentical placebo administered orally |
| Name | Type | Description |
|---|---|---|
| Schedule A | DRUG | Dosing 1 hour before breakfast |
| Schedule B | DRUG | Dosing 0.5 hour before breakfast |
| Schedule C | DRUG | Dosing immediately before breakfast |
| Schedule D | DRUG | Dosing immediately before lunch |
| Schedule E | DRUG | Split dose, dosing 1 hour before breakfast and dinner |
Inclusion Criteria: * Adults ≥18 and ≤55 years of age * Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mm Hg; diastolic blood pressure, 50-90 mm Hg; heart rate, 50-100 bpm * Body mass index (BMI) ≥18 and ≤35 kg/sq m * Able to provide written informed consent Excl...
Schedule A is an investigational small molecule being developed by Lexicon Pharmaceuticals, Inc. It has completed a Phase 1 clinical trial in healthy adult volunteers. The specific therapeutic indication for Schedule A has not been publicly disclosed, and the compound remains in early-stage clinical development.
Schedule A is being developed by Lexicon Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker symbol LXRX. Lexicon is the sponsor of the clinical program for this investigational small molecule.
Schedule A is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The program remains investigational and has not been approved by the FDA for any indication.
Schedule A has been studied in one completed Phase 1 trial, NCT01334242, titled "A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects." The trial enrolled 14 healthy adult volunteers in the United States and was randomized, double-blind, and placebo-controlled.
Yes, Schedule A is also known as LX4211. The completed Phase 1 trial NCT01334242 was conducted under the LX4211 designation, so references to LX4211 in the clinical literature refer to the same investigational compound being developed by Lexicon Pharmaceuticals.